Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | MAX | P61244 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27087116 | 0.89 | MYC (0.42) | ATMMYCMAXABCB1ALDH1A1 | |
| SCHEMBL27087120 | 0.89 | MYC (0.42) | ATMMYCMAXABCB1ALDH1A1 | |
| SCHEMBL29919587 | 0.86 | BCL2 (0.47) | BCL2MCL1ATMMYCMAX | |
| SCHEMBL22120986 | 0.84 | BCL2 (0.47) | BCL2MCL1ATMMYCMAX | |
| SCHEMBL29162420 | 0.82 | ACE (0.54) | BCL2MCL1PTPN1PPARA | |
| SCHEMBL4898325 | 0.81 | ATM (0.60) | ATMAPPSYKAKT1 | |
| SCHEMBL4900744 | 0.81 | ATM (0.60) | ATMAPPSYKAKT1 | |
| SCHEMBL12336762 | 0.81 | ATM (0.60) | ATMAPPSYKAKT1 | |
| SCHEMBL29919848 | 0.80 | BCL2 (0.52) | BCL2MCL1PPARA | |
| SCHEMBL1731189 | 0.80 | BCL2 (0.52) | BCL2MCL1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
| WO-2022216750-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.